MapLight Therapeutics, Inc. ( (MPLT) ) has released its Q3 earnings. Here is a breakdown of the information MapLight Therapeutics, Inc. presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing treatments for central nervous system disorders, leveraging its expertise in psychiatry and neuroscience research to create circuit-specific pharmacotherapies.
In its latest earnings report, MapLight Therapeutics highlighted significant progress in its drug development pipeline and financial standing. The company successfully completed an initial public offering, raising substantial funds to support its operations through 2027.
Key financial metrics from the third quarter of 2025 include a net loss of $29.4 million, an increase from the previous year, attributed to higher research and development expenses. The company ended the quarter with $227.2 million in cash and investments, bolstered by the proceeds from its recent public offering. MapLight is advancing several clinical trials, with expected results from its Phase 2 studies for schizophrenia and Alzheimer’s disease psychosis in 2026 and 2027, respectively.
MapLight’s strategic focus remains on advancing its diverse pipeline of therapies for CNS disorders. The company is on track with its clinical trials, including the IRIS study for autism spectrum disorder and the development of treatments for Parkinson’s disease and hyperactivity-related disorders.
Looking forward, MapLight Therapeutics is poised to continue its momentum in drug development, supported by a strong financial position and a clear focus on addressing unmet needs in CNS disorders.